Nanotechnology and therapeutic delivery: A drug regulation perspective

Therapeutic Delivery

Volumn 1, Issue 1, 2010, Pages 83-89

  Sadrieh, Nakissa ^a   Tyner, Katherine M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANGIOPEPTIN; APREPITANT; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; DRUG VEHICLE; ESTRADIOL; FENOFIBRATE; FERUMOXYTOL; LIPOSOME; MEGESTROL ACETATE; METAL OXIDE; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; RAPAMYCIN; VERTEPORFIN;

DRUG APPROVAL; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG PENETRATION; DRUG RELEASE; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; GOOD LABORATORY PRACTICE; HEALTH HAZARD; INTERNATIONAL COOPERATION; NANOMEDICINE; PHARMACEUTICAL ENGINEERING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW;

EID: 79954993034     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.6     Document Type: Review

References (19)

1. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin. Chim. Acta 358, 37-54 (2005). (Pubitemid 40966630)
2. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36, 43-48 (2008).
3. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30(11), 592-599 (2009).
4. McCarthy TD, Karellas P, Henderson SA et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimers-based microbicides for HIV and STI prevention. Mol. Pharm. 2(4), 312-318 (2005). (Pubitemid 41186407)
5. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status Anticancer Drugs 19, 899-909 (2008).
6. Gutierrez JM, Gonzalez C, Maestro A, Sole I, Pey CM, Nolla J. Nano-emulsions: new applications and optimization of their preparation. Curr. Opin. Colloid Interface Sci. 13, 245-251 (2008). (Pubitemid 351818213)
7. Lila ASA, Ishida T, Kiwada H. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin. Drug Deliv. 6(12), 1297-1309 (2009).
8. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med. 234(2), 123-131 (2009).
9. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 26(10), 552-558 (2008).
10. Barbu E, Molnar E, Tsibouklis J, Gorecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin. Drug Deliv. 6(6), 553-565 (2009).
11. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 21(10), 1184-1191 (2003). (Pubitemid 37186175)
12. Leary SP, Liu CY, Apuzzo MLJ. Toward the emergence of nanoneurosugery: part III - nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosugery. Neurosurgery 58, 1009-1026 (2006).
13. National Science and Technology Council, Committee on Technology, Subcommittee on Nanoscale Science, Engineering, and Technology: The National Nanotechnology Initiative Strategic Plan (2007).
14. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine 2(6), 789-803 (2007).
15. De Jong WJ, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 3(2), 133-149 (2008). (Pubitemid 352042401)
16. Zogovic NS, Nikolic NS, Vranjes-Djuric SD et al. Opposite effects of nanocrystalline fullerene (C60) on tumor cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C60. Biomaterials 30, 6940-6946 (2009).
17. Lacerda SHDP, Park JJ, Meuse C et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4(1), 365-379 (2010).
18. Tinkle S, Teague EC, Earles TM, Holdridge GM. The national nanotechnology initiative. Supplement to President's 2010 Budget (2009) www.nano.gov/NNI-2010- budget- supplement.pdf (Accessed 1 December 2010)
19. US FDA Guidance www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/default.htm